Alcohol septal ablation for hypertrophic obstructive cardiomyopathy pathophysiology of gradient reduction

Jump to navigation Jump to search

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Nehal Eid, M.D.[2]

Pathophysiology of Gradient Reduction

Alcohol septal ablation (ASA) reduces dynamic left ventricular outflow tract (LVOT) obstruction by creating a localized infarction in the basal septum at the point of systolic anterior motion–septal contact. Gradient relief begins with acute loss of contractility in the target segment and continues through scar formation, septal thinning, LVOT widening, reduction of systolic anterior motion, and ventricular reverse remodeling.

Pathophysiologic substrate targeted by ASA

LVOT obstruction in hypertrophic cardiomyopathy (HCM) results from the interaction between asymmetric basal septal hypertrophy and systolic anterior motion of the mitral valve (SAM), which progressively narrows the outflow tract during systole.[1]

SAM is driven predominantly by drag forces rather than by the historically proposed Venturi effect. Early systolic flow deflected by the septal bulge, together with isovolumic vortical flow, strikes the posterior surface of anteriorly displaced mitral leaflets and pushes them toward the septum.[2][3] SAM begins before aortic valve opening in approximately 40% of patients, when LVOT velocity is insufficient to generate substantial Venturi suction.[2][4]

Anatomic contributors that amplify drag-mediated SAM include:

  • Elongated mitral leaflets with residual leaflet tissue extending into the LVOT
  • Anterior or apical displacement of the papillary muscles
  • Papillary muscle hypertrophy, bifidity, or anomalous direct insertion into the anterior mitral leaflet
  • A small LV cavity with hyperdynamic systolic function[4][1]

SAM-septal contact produces dynamic LVOT obstruction and impairs mitral leaflet coaptation, commonly causing posteriorly directed mitral regurgitation (MR).[5][1] Because the obstruction is dynamic, it increases with reduced preload, reduced afterload, or increased contractility.

Controlled ethanol-induced septal infarction

ASA delivers a small volume of absolute ethanol, typically 1.5–2.5 mL, into a septal perforator supplying the basal anterior septum at the SAM-septal contact point.[1][6] Ethanol produces direct cytotoxic injury and local thrombosis, resulting in coagulative necrosis of the supplied myocardium.[7]

The resulting controlled infarction usually involves approximately 5%–10% of LV mass.[7] Its hemodynamic effectiveness depends primarily on whether the infarction involves the basal septum at the site of SAM contact. A larger infarction does not necessarily produce greater gradient reduction.

Intraprocedural myocardial contrast echocardiography identifies whether the selected perforator supplies the intended contact zone and excludes perfusion of nontarget structures such as the papillary muscles, right ventricular free wall, or anterolateral LV wall.[4] This anatomic matching is the mechanistic basis for contrast-guided targeting.

Temporal course of gradient reduction

Gradient reduction develops through acute and chronic phases.

Phase Myocardial change Hemodynamic effect
Acute: intraprocedural to several days Immediate akinesia of the infarcted basal septal segment Reduced systolic septal encroachment widens the functional LVOT. The LVOT gradient and left atrial pressure decrease, while aortic pulse pressure increases.[6][8][9]
Early remodeling: weeks to approximately 3 months Necrotic myocardium is replaced by scar, followed by scar contraction and progressive thinning of the treated septum. Structural widening of the LVOT further decreases flow-mediated drag, SAM-septal contact, and the residual gradient.[6][10]
Late remodeling: 3–12 months Continued septal thinning and global reverse remodeling Additional gradient reduction may occur after the early procedural assessment. Changes in LVOT obstruction and scar formation are usually complete by approximately 3 months but may continue for up to 1 year.[11]

Serial cardiac magnetic resonance imaging studies demonstrate that septal mass reduction begins within the first month and continues through at least 6 months. Early thinning is greatest when the infarction is transmural or predominantly involves the left side of the interventricular septum.[12]

An immediate gradient decrease therefore does not represent the complete effect of ASA, and an early residual gradient does not necessarily indicate definitive procedural failure.[11]

Reduction of SAM and mitral regurgitation

Septal remodeling interrupts the hemodynamic cycle that sustains obstruction:

  1. Septal akinesia and thinning widen the LVOT.
  2. LVOT widening redirects systolic flow and reduces drag on the mitral leaflets.
  3. Reduced drag decreases SAM-septal contact and dynamic obstruction.
  4. Reduced SAM improves mitral leaflet coaptation and decreases SAM-mediated MR.
  5. Gradient and MR reduction lower LV filling pressure, left atrial pressure, and pulmonary artery pressure.[5][9]


ASA improves MR only when regurgitation is caused predominantly by SAM-related leaflet malcoaptation. MR severity improves in approximately 67% of patients after ASA, and the degree of MR improvement correlates with gradient reduction.[13][14] ASA does not correct intrinsic leaflet disease, anomalous papillary muscle insertion, or another primary mitral apparatus abnormality.[5][10]

Remote and biventricular reverse remodeling

The structural response extends beyond the infarcted basal septum. Relief of LVOT obstruction reduces intracavitary systolic pressure and ventricular afterload, permitting regression of noninfarcted LV mass. The magnitude of remote LV mass reduction correlates with the degree of gradient reduction.[12]

In one CMR series, remote noninfarcted LV mass decreased from 141 ± 41 g to 111 ± 27 g at 6 months after ASA.[12] Biventricular reverse remodeling has also been demonstrated, with significant reductions in LV and RV mass. The magnitude of RV mass reduction correlated with LVOT gradient reduction (r = 0.535, p = 0.001).[15]

Greater reverse remodeling is associated with improvement in diastolic function, including reduction in E/e', and with better long-term composite outcomes. Higher pre-ablation LV mass is associated with less favorable reverse remodeling.[16]

These findings support the concept that part of the hypertrophy in obstructive HCM is load-dependent and reversible rather than entirely determined by the underlying myocardial phenotype. Reduced wall stress, lower filling pressure, and improved mitral valve function may further stabilize the hemodynamic response.

Despite a controlled infarction involving 5%–10% of LV mass, LV ejection fraction remains >55% in approximately 97% of patients over medium-term follow-up.[13]

Determinants and limitations of gradient relief

Determinant Pathophysiologic significance
Basal infarct location Infarction must overlap the basal septal region responsible for SAM-septal contact. Basal location, rather than larger infarct size, is associated with successful gradient reduction.[17]
Septal perforator territory Coronary anatomy determines whether ethanol can reach the critical obstructing segment. A perforator supplying a distal or nontarget region may create scar without adequately reducing SAM-septal contact.[6][4]
Extent of infarction The infarction must be sufficient to produce focal akinesia and subsequent thinning, but increasing infarct size does not provide proportional hemodynamic benefit when the critical basal contact zone is not included.[7][17]
Pre-existing septal fibrosis Patients with late gadolinium enhancement before ASA have a higher frequency of residual LVOT gradient >30 mmHg than patients without enhancement (13% versus 2%), although ASA remains effective overall. The association does not establish that pre-existing fibrosis directly causes treatment failure.[18]
Obstruction outside the target zone Midventricular obstruction, fixed subaortic obstruction, or obstruction caused primarily by intrinsic mitral or papillary muscle pathology will persist because ASA acts only through the perfused septal territory.[10][5]
Acute hemodynamic response Baseline mean left atrial pressure >19 mmHg was associated with worse survival (HR 2.70). Intraprocedural LVOT gradient reduction <82% and aortic pulse pressure increase <19% also predicted worse long-term survival. These are prognostic associations rather than validated causal thresholds for gradient relief.[8]
Remodeling interval Gradient reduction may continue for 3–12 months as scar contracts and the septum thins; premature assessment can underestimate the final hemodynamic response.[11]
Center and operator experience A volume-outcome relationship has been documented. Patients treated during a center's first 50 procedures had significantly lower odds of complete clinical and hemodynamic response (OR 0.49).[19]

Proarrhythmic potential of the iatrogenic scar

ASA intentionally creates myocardial scar, which adds to the total late gadolinium enhancement burden on CMR. Native HCM-related LGE is a recognized risk marker for sudden cardiac death, but it remains uncertain whether a localized ASA-induced scar carries the same arrhythmic significance as native myocardial fibrosis.[7][20]

Large registries have not demonstrated a consistent increase in late LV dysfunction or sudden cardiac death attributable to the ASA-induced scar. Some observational cohorts have reported long-term survival comparable to surgical myectomy cohorts, although these comparisons remain subject to differences in patient selection.[21][7] The long-term proarrhythmic significance of the iatrogenic scar remains under investigation.

References

  1. ↑ 1.0 1.1 1.2 1.3 Veselka J, Anavekar NS, Charron P (2017). "Hypertrophic Obstructive Cardiomyopathy". Lancet. 389 (10075): 1253–1267. doi:10.1016/S0140-6736(16)31321-6. PMID 27912983.
  2. ↑ 2.0 2.1 Ro R, Halpern D, Sahn DJ; et al. (2014). "Vector Flow Mapping in Obstructive Hypertrophic Cardiomyopathy to Assess the Relationship of Early Systolic Left Ventricular Flow and the Mitral Valve". J Am Coll Cardiol. 64 (19): 1984–1995. doi:10.1016/j.jacc.2014.04.090. PMID 25440093.
  3. ↑ Guigui SA, Torres C, Escolar E, Mihos CG (2022). "Systolic Anterior Motion of the Mitral Valve in Hypertrophic Cardiomyopathy: A Narrative Review". J Thorac Dis. 14 (6): 2309–2325. doi:10.21037/jtd-22-182. PMID 35813751 Check |pmid= value (help).
  4. ↑ 4.0 4.1 4.2 4.3 Nagueh SF, Phelan D, Abraham T; et al. (2022). "Recommendations for Multimodality Cardiovascular Imaging of Patients With Hypertrophic Cardiomyopathy: An Update From the American Society of Echocardiography, in Collaboration With the American Society of Nuclear Cardiology, the Society for Cardiovascular Magnetic Resonance, and the Society of Cardiovascular Computed Tomography". J Am Soc Echocardiogr. 35 (6): 533–569. doi:10.1016/j.echo.2022.03.012.
  5. ↑ 5.0 5.1 5.2 5.3 Shuvy M, Postell YY, Carasso S; et al. (2024). "Mitral Valve Interventions for Hypertrophic Obstructive Cardiomyopathy". Can J Cardiol. 40 (5): 860–868. doi:10.1016/j.cjca.2023.12.009. PMID 38110174 Check |pmid= value (help).
  6. ↑ 6.0 6.1 6.2 6.3 Bali AD, Malik A, Naidu SS (2024). "Treatment Strategies for Hypertrophic Cardiomyopathy: Alcohol Septal Ablation and Procedural Step-by-Step Technique". Am J Cardiol. 212S: S42–S52. doi:10.1016/j.amjcard.2023.10.064. PMID 38368036 Check |pmid= value (help).
  7. ↑ 7.0 7.1 7.2 7.3 7.4 Sorajja P (2017). "Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy: A Word of Balance". J Am Coll Cardiol. 70 (4): 489–494. doi:10.1016/j.jacc.2017.06.011. PMID 28728695.
  8. ↑ 8.0 8.1 Alabdaljabar MS, Cendrowski EE, Nishimura RA; et al. (2023). "Hemodynamic Predictors of Outcome Following Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy". Circ Cardiovasc Interv. 16 (8): e013068. doi:10.1161/CIRCINTERVENTIONS.123.013068. PMID 37582173 Check |pmid= value (help).
  9. ↑ 9.0 9.1 Sorajja P, Nishimura RA, Ommen SR; et al. (2008). "Effect of Septal Ablation on Myocardial Relaxation and Left Atrial Pressure in Hypertrophic Cardiomyopathy: An Invasive Hemodynamic Study". JACC Cardiovasc Interv. 1 (5): 552–560. doi:10.1016/j.jcin.2008.07.004. PMID 19463358.
  10. ↑ 10.0 10.1 10.2 Nishimura RA, Holmes DR (2004). "Hypertrophic Obstructive Cardiomyopathy". N Engl J Med. 350 (13): 1320–1327. doi:10.1056/NEJMcp030779.
  11. ↑ 11.0 11.1 11.2 Ommen SR, Ho CY, Asif IM; et al. (2024). "2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines". J Am Coll Cardiol. 83 (23): 2324–2405. doi:10.1016/j.jacc.2024.02.014.
  12. ↑ 12.0 12.1 12.2 van Dockum WG, Beek AM, ten Cate FJ; et al. (2005). "Early Onset and Progression of Left Ventricular Remodeling After Alcohol Septal Ablation in Hypertrophic Obstructive Cardiomyopathy". Circulation. 111 (19): 2503–2508. doi:10.1161/01.CIR.0000165084.28065.01. PMID 15867172.
  13. ↑ 13.0 13.1 Moss TJ, Krantz MJ, Zipse MM; et al. (2014). "Left Ventricular Systolic Function Following Alcohol Septal Ablation for Symptomatic Hypertrophic Cardiomyopathy". Am J Cardiol. 113 (8): 1401–1404. doi:10.1016/j.amjcard.2014.01.417. PMID 24576545.
  14. ↑ He YG, Dong Y, Yang SH; et al. (2024). "Short Time Effects of Two Radiofrequency Ablation Methods on Hypertrophic Obstructive Cardiomyopathy". Clin Cardiol. 47 (3): e24217. doi:10.1002/clc.24217.
  15. ↑ Chen YZ, Qiao SB, Hu FH; et al. (2015). "Biventricular Reverse Remodeling After Successful Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy". Am J Cardiol. 115 (4): 493–498. doi:10.1016/j.amjcard.2014.11.030. PMID 25541323.
  16. ↑ Duan FJ, Chen YZ, Yuan JS, Zhang Y, Qiao SB (2023). "Association Between Left Ventricular Reverse Remodeling and Long-Term Outcomes After Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy". Int J Cardiovasc Imaging. 39 (2): 423–432. doi:10.1007/s10554-022-02735-4. PMID 36322263 Check |pmid= value (help).
  17. ↑ 17.0 17.1 Steggerda RC, Geluk CA, Brouwer W; et al. (2015). "Basal Infarct Location but Not Larger Infarct Size Is Associated With a Successful Outcome After Alcohol Septal Ablation in Patients With Hypertrophic Obstructive Cardiomyopathy: A Cardiovascular Magnetic Resonance Imaging Study". Int J Cardiovasc Imaging. 31 (4): 831–839. doi:10.1007/s10554-015-0606-1. PMID 25638485.
  18. ↑ Polaková E, Liebregts M, Marková N; et al. (2020). "Effectiveness of Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy in Patients With Late Gadolinium Enhancement on Cardiac Magnetic Resonance". Int J Cardiol. 319: 101–105. doi:10.1016/j.ijcard.2020.06.049. PMID 32682963 Check |pmid= value (help).
  19. ↑ Veselka J, Liebregts M, Cooper R; et al. (2025). "Impact of Centre Experience on Complete Clinical and Haemodynamic Response After Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy". Int J Cardiol: 133865. doi:10.1016/j.ijcard.2025.133865. PMID 40921283 Check |pmid= value (help).
  20. ↑ Maron BJ, Desai MY, Nishimura RA; et al. (2022). "Management of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review". J Am Coll Cardiol. 79 (4): 390–414. doi:10.1016/j.jacc.2021.11.021. PMID 35086661 Check |pmid= value (help).
  21. ↑ Batzner A, Pfeiffer B, Neugebauer A; et al. (2018). "Survival After Alcohol Septal Ablation in Patients With Hypertrophic Obstructive Cardiomyopathy". J Am Coll Cardiol. 72 (24): 3087–3094. doi:10.1016/j.jacc.2018.09.064. PMID 30545446.
Retrieved from "https://www.wikidoc.org/index.php?title=Alcohol_septal_ablation_for_hypertrophic_obstructive_cardiomyopathy_pathophysiology_of_gradient_reduction&oldid=1745529"